TNF and histiocytic sarcoma: With regard to the last approved TNFα inhibitor, the humanized antibody IgG4 Certolizumab pegol, the effectiveness in HS across the published studies is promising, but, due to the still insufficient data, its role in HS warrants further investigation (33).